{"name":"Dendreon","slug":"dendreon","ticker":"","exchange":"","domain":"","description":"Dendreon Pharmaceuticals LLC is a biotechnology company. Its lead product, Provenge, is an immunotherapy for prostate cancer. It consists of a mixture of the patient's own blood cells that have been incubated with the Dendreon PAP-GM-CSF fusion protein.\nPhase III clinical trial results demonstrating a survival benefit for prostate cancer patients receiving the drug were presented at the AUA meeting on April 28, 2009. After going through the approval process, Provenge was given full approval by the FDA on April 29, 2010. Dendreon's stock value fell 66% on August 4, 2011, after abandoning its forecast for its debut drug Provenge.","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":283746000,"revenueGrowth":279.2,"grossMargin":0,"rdSpend":70833000,"netIncome":-296804000,"cash":434401000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2013"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"APC8015F","genericName":"APC8015F","slug":"apc8015f","indication":"Prostate cancer","status":"phase_2"}]}],"pipeline":[{"name":"APC8015F","genericName":"APC8015F","slug":"apc8015f","phase":"phase_2","mechanism":"APC8015F is a therapeutic cancer vaccine designed to stimulate an immune response against prostate cancer cells.","indications":["Prostate cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOM2lpQWtJTklKUUtXRlVqTUtjNFV0MzdkckdPNUNnbGNmSEhOOE5jMkFlcm5DR2IzNXNMb0M1b3lLZHFtYzNabUppdGhtQjJUU0hKZzlKR2tad2E1M0h3V2w2V09KZnYwWldUNWFKbzdBYzJhOE5uQkpKcGhoWjJ2c3R2dk44bTNyYVhJ?oc=5","date":"2025-08-19","type":"pipeline","source":"Pharma Voice","summary":"In cell therapy, cost is a hot issue. The industry might need a cold solution. - Pharma Voice","headline":"In cell therapy, cost is a hot issue. The industry might need a cold solution.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPZlczSUVRaHZ0d1MwdHNPYThZX05sS2VTRDF4OWgtNW9ubktVUVBqSnZ2anAwZm1qSWRaMmEzS3hFNU1fa2k5RFd0OFJOcW9XajBnQXl3WExDdmZIdnhFaF8yWlMydFN1bzBaWVBjc181MERLaVlfeld5enl4dHpDdC1UbEltb1piQ0hZcHNPZVZlN2RxTHgyVUIyQjBKOU1tcGR5UUVkbmo5Zw?oc=5","date":"2025-03-14","type":"pipeline","source":"Pharmaceutical Technology","summary":"Unsafe and unregulated cell therapies being sold in Europe - Pharmaceutical Technology","headline":"Unsafe and unregulated cell therapies being sold in Europe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE9ieXJZQzlWMEtDbWtRTDZxd0tNSldZTE1rTjBQbndaU0JyNTJBMVcyZF9WdEo5bldUOFV3cVVBYVFMMk5UbnpMWTIxV3JheUR0N0E0R0xJeU0zb1V0amg4TWIzYnU3b3Fqa1hzUnMyMGR6RHJLS293VTZR?oc=5","date":"2025-02-26","type":"pipeline","source":"Pharma Voice","summary":"Cancer vaccines have stumbled, but the approach is gaining new steam - Pharma Voice","headline":"Cancer vaccines have stumbled, but the approach is gaining new steam","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQT3p1TnZfX0ltMDRyWC1Gb0lIVXB4YWpvT01xYVFVWGlKUkNRTjZHZnMyM2dvb0wyNHFWTVg3d0xUQ2NyUG12N2w3NW14eDVuWWhET1N5Z0NZSUl1dzVmdFhDY3Z0czlNYy1kSUdJMWZIYUNJbnRZVV92QnFKeVcwS0puODVxckE5WEZRZ2t1MzBSMmI1cFBN?oc=5","date":"2021-11-19","type":"pipeline","source":"SHRM","summary":"Pandemic Turns Pharma Industry Upside Down - SHRM","headline":"Pandemic Turns Pharma Industry Upside Down","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxOWTFSRmM0bnl0bUQxX29mQmd3ZlNZT2s4YngtTTNXRS0wWWlYZ3J5NUdUVVJ0UE1KYXVCT3pfcnBZWlRQM2lVTnJqOWlEblM1SXFhV3pleWthX0h1LXF2dXJvSkZsY2pYUXh6dzVBYWpuek81WjFyQ0N5Wkd3enY3UjVIVnpOYjE5djB6MGt0em1xajNIblFOSl92dW9Zc09nV3NIT3pvMFBoUWZyeDA2X0NtZjgwSmlxaWp5Z3NLSGxYUG1fV3ROa1JUU04wNm8?oc=5","date":"2021-11-08","type":"pipeline","source":"Contract Pharma","summary":"Dendreon and Shoreline Enter CMC Agreement - Contract Pharma","headline":"Dendreon and Shoreline Enter CMC Agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQakVYeWZOT1NMRm5XWVlwTGVOUUNwNHhhbC1LSVZpQWpYaFFDTW1LRV9zVmxtNkZmeE1ob0xaUnhoLWtfSVFKV3d0UXhxNl81eUI1VzdmLTVmY0wxdEE1VzFWMHZFZ0FIVlhzd0xub3ZOUVdDaHpCcXF1N01kWkp6dnN1V2lxWTZsSlZ1WnZENA?oc=5","date":"2021-06-29","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"Second Path: Dendreon Seeks Growth beyond Provenge - Genetic Engineering and Biotechnology News","headline":"Second Path: Dendreon Seeks Growth beyond Provenge","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxQRFRhZkZrVnJ6cGNKLUFGMWJNR01qQjhtM002cWgtRjIzd2RlTGJGTmg0UVRyMm1nZGRTQmUxQW10Y1F1dnl3MWpnUFhnaGxSdTlxWnZDLXh6aGVNZklCNm1iTkRRcTB0MkJhV0xmelJna0NtdVFQQ2RKZ2dHd3ZTdTFHd0pZdFdiNmIyUllGZ3lmdzBYODUtcWthSTlPdGhwMENna0hDSkotenl1T2RFeXgzM0tBNFZINGFyZUhJNWhXZUZDUEFZ?oc=5","date":"2021-06-17","type":"deal","source":"Fierce Pharma","summary":"Long-suffering Dendreon finds new avatar as contract manufacturer for cell therapy partners - Fierce Pharma","headline":"Long-suffering Dendreon finds new avatar as contract manufacturer for cell therapy partners","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQRjVXMlB6ZXFaX0cyLVRHRjJ0eXFWVGcxUDRSM1d3VGNFN2FpV0hoMmpoa0JIdUU4NFd6d29UVjd5RHRkanY1Q1pUTVk0M0FYWkVpODVvSW94S2poWHNBZWJrVzkzbG5FME1WVk1IQl8xTFJPd1Y4RjhGSHlldmg3ZG1OMzhxZG1GRFdUdGowN3MxUQ?oc=5","date":"2018-08-03","type":"deal","source":"Fierce Pharma","summary":"Dendreon changes hands—again—in $868M deal that keeps seller Sanpower in the game - Fierce Pharma","headline":"Dendreon changes hands—again—in $868M deal that keeps seller Sanpower in the game","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE10LXFDYW1EZjNmVUJhUkIzXzJjOHo3OXVuZnU3OWx5Y1E5TDBzZnNWYTRPeUNESDlpMUxqMG5HeXFIWXVxdDhoMmtBeTM4dWdSVXZxWFp4Rmt5dGhrS215cjdhS2lGb0IzQ2lTMUVScm85VGF3Z05VNDloYjI?oc=5","date":"2017-01-10","type":"pipeline","source":"BioPharma Dive","summary":"JPM: Valeant sells off Dendreon, skincare brands for $2.1B - BioPharma Dive","headline":"JPM: Valeant sells off Dendreon, skincare brands for $2.1B","sentiment":"neutral"},{"date":"2015-06-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2015-06-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2015-06-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2015-05-21","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2015-04-21","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2015-04-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":283746000,"revenuePeriod":"2013-12-31","revenueHistory":[{"value":283746000,"period":"2013-12-31"},{"value":74835000,"period":"2013-12-31"},{"value":68002000,"period":"2013-09-30"},{"value":73315000,"period":"2013-06-30"},{"value":67594000,"period":"2013-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":70833000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-296804000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":434401000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}